0000000001178007

AUTHOR

Alfonso Bermejo

showing 2 related works from this author

The impact of using the combined oral contraceptive pill for cycle scheduling on gene expression related to endometrial receptivity.

2014

STUDY QUESTION: Does the combined oral contraceptive pill (COCP) change endometrial gene expression when used for cycle programming? SUMMARY ANSWER: COCP used for scheduling purposes does not have a significant impact on endometrial gene expression related to endometrial receptivity. WHAT IS KNOWN ALREADY: Controversy exists around COCP pretreatment for IVF cycle programming as some authors claim that it might be detrimental to the live birth rate. Microarray technology applied to the study of tissue gene expression has previously revealed the behavior of genes related to endometrial receptivity under different conditions. STUDY DESIGN SIZE AND DURATION: Proof-of-concept study of 10 young h…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationUterusGene ExpressionEndometriumEndometriumYoung AdultOvulation InductionmedicineHumansEmbryo ImplantationeducationMenstrual CycleGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testGenitourinary systembusiness.industryRehabilitationObstetrics and Gynecologymedicine.diseaseContraceptives Oral Combinedmedicine.anatomical_structureReproductive MedicineFemaleCombined oral contraceptive pillLive birthbusinessEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct